Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers Multicore, a suite of integrated synthetic methods that gives access to complex drug-like molecules; and ionX, an integrated platform of genomics discoveries and technologies that serves as the foundation for Bionomics' CNS drug discovery and development, as well as contract research services. The company has a collaborative partnership with Merck & Co., Inc. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+61-8-83546100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.88 million
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
Bionomics (ASX:BNO) Frequently Asked Questions
What is Bionomics' stock symbol?
Bionomics trades on the ASX under the ticker symbol "BNO."
Has Bionomics been receiving favorable news coverage?
News articles about BNO stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Bionomics earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Bionomics' key competitors?
Some companies that are related to Bionomics include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are Bionomics' key executives?
Bionomics' management team includes the folowing people:
- Dr. Errol B. De Souza, Exec. Chairman (Age 65)
- Dr. Deborah Ann Rathjen B.Sc. (Hons.), Q.C., Ph.D., M.A.I.C.D., FTSE, Chief Exec. Officer (Age 60)
- Mr. Jack Moschakis BEc, DipLaw(BAB), GDipBA, FCIS, Legal Counsel & Company Sec.
- Prof. Paul Rolan, Consultant Medical Officer of Clinical Neuroscience
What is Bionomics' stock price today?
One share of BNO stock can currently be purchased for approximately A$0.13.
What is Bionomics' official website?
How can I contact Bionomics?
Bionomics' mailing address is 31 Dalgleish St, THEBARTON, SA 5031, Australia. The company can be reached via phone at +61-8-83546100.
MarketBeat Community Rating for Bionomics (ASX BNO)
MarketBeat's community ratings are surveys of what our community members think about Bionomics and other stocks. Vote "Outperform" if you believe BNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
